Paraproteinemias: all 69 studies
Page 1 of 1. Open to participants first (22), then studies with results posted, then the rest; newest registration first within each.
- This Study Aims to Investigate the Efficacy of Photobiomodulation in the Treatment of Anti-MAG-induced Peripheral Neuropathy (LASER-MAG)Enrolling by invitationNCT07661667
- Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine ImagingNot yet recruitingNCT07624760Not applicable
- Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and TreatmentRecruitingNCT07448779
- Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell DisordersNot yet recruitingNCT07365059Early Phase 1
- A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT07075185Phase 1
- The Effect of Daratumumab in Patients With Monoclonal Gammopathy of Renal Significance (MGRS) in FinlandRecruitingNCT06889948Phase 2
- Pre-malignant States to Hematologic Malignancies in FirefightersRecruitingNCT06870760
- Dara-BCD for Rare MGRSNot yet recruitingNCT06771180Phase 2
- Multi-center Screening for Serum M ProteinNot yet recruitingNCT06750965
- BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple MyelomaRecruitingNCT06644443Phase 1/2
- Screening for Monoclonal Gammopathy in Individuals Undergoing Physical Examinations Using iMS-LC Assay Technology.Not yet recruitingNCT06489613
- A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL StudyRecruitingNCT06271252Phase 1
- GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple MyelomaRecruitingNCT05992532
- Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS AnalysisRecruitingNCT05686447
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide RefractoryNot yet recruitingNCT05581875Phase 1/2
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple MyelomaRecruitingNCT05573802Phase 1/2
- A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome InhibitorNot yet recruitingNCT05298683Phase 2
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleRecruitingNCT05280275Phase 1/2
- Autologous Stem Cell Transplantation for Patients With AL AmyloidosisEnrolling by invitationNCT04210791
- The Indiana Myeloma RegistryRecruitingNCT03616483
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT02012699
- Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample ResourceRecruitingNCT01408225
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Phase 2Results posted
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)Active, not recruitingNCT04512235Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)Active, not recruitingNCT04504825Phase 3Results posted
- Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple MyelomaActive, not recruitingNCT03236428Phase 2Results posted
- The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) AmyloidosisCompletedNCT02632786Phase 2Results posted
- Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
- Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior TreatmentTerminatedNCT01548573Phase 2Results posted
- Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple MyelomaCompletedNCT01447914Phase 2Results posted
- Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple MyelomaCompletedNCT01345019Phase 3Results posted
- Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS DeviceCompletedNCT01210716Phase 3Results posted
- A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01063907Phase 1/2Results posted
- Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01002755Phase 2Results posted
- Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)CompletedNCT00773747Phase 3Results posted
- Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)TerminatedNCT00579111Phase 1/2Results posted
- Monoclonal Gammopathy With Clinical Significance in Patients With and Without Haematological Malignancies in Finistère Between 2012 and 2017 (GammaClinik)CompletedNCT06559579
- Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT05804032Phase 3
- Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell TherapyWithdrawnNCT05362331Not applicable
- A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal ImpairmentStatus unknownNCT05147493Phase 2
- MGRS: Clinical-histological Features of a Multicenter Case SeriesCompletedNCT05119309
- Isatuximab in Patients With Monoclonal Gammopathy of Renal SignificanceActive, not recruitingNCT04614558Phase 2
- Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple MyelomaStatus unknownNCT04309084Phase 1
- Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler SyndromeWithdrawnNCT04213274Phase 2
- Frequency and Characteristics of Pruritus in Patients With Monoclonal GammopathyCompletedNCT03832140
- Rifaximin in Patients With Monoclonal GammopathyCompletedNCT03820817Phase 1
- Diagnosis of MGRS in Patients With Paraproteinemias: Clinical, Anatomopathological and Pathophysiological StudyStatus unknownNCT03629561
- Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering MyelomaWithdrawnNCT03591614Early Phase 1
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingNCT02952508Phase 2
- Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial FatWithdrawnNCT02920190Phase 4
- A Diagnostic Screening Trial Seeking AL Amyloidosis Very EarlyCompletedNCT02741999
- Pilot Trial of Homebound Stem Cell TransplantationActive, not recruitingNCT02671448Not applicable
- Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance ImagingWithdrawnNCT02462213
- Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in MyelomaWithdrawnNCT02155634Phase 3
- Comprehensive Frailty AssessmentCompletedNCT02033928
- Study of Hypotensive Hematopoietic Malignancy Patients' USCOM ReadingsCompletedNCT01755000Not applicable
- Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal GammopathyCompletedNCT01543100Not applicable
- A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01248923Phase 1
- Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)CompletedNCT01186224Not applicable
- Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple MyelomaCompletedNCT01183949Phase 1/2
- A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00821249Phase 1/2
- A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple MyelomaCompletedNCT00725634Phase 1
- Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple MyelomaCompletedNCT00525447Phase 1
- Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With TuberculosisStatus unknownNCT00173264
- Study of Epratuzumab (hLL2) in Patients With Waldenstrom's MacroglobulinemiaTerminatedNCT00113802Phase 2
- Study of SGN-40 in Patients With Refractory or Recurrent Multiple MyelomaCompletedNCT00079716Phase 1
- Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1HCompletedNCT00048412Phase 1/2
- Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT00001287Phase 2